Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN · NASDAQ Global Market
+$0.52 today
Vol 1.11M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lyn Baranowski | CEO, President & Director | $804,500.00 | — | 50 | — | — |
Howard Lazarus | Chief Medical Officer | $667,453.00 | — | 60 | — | — |
Douglas R. Carlson | CFO & Chief Business Officer | $656,000.00 | — | 47 | — | — |
Melissa Rhodes DABT | Chief Operating Officer | $635,200.00 | — | 48 | — | — |
Craig Conoscenti | Senior Vice President of Clinical Development | — | — | — | — | — |
Stephen Pham | Senior Vice President of Product Development | — | — | — | — | — |
Adam Golden | General Counsel & Head of Business Development | — | — | 62 | — | — |
James Bishop | Senior Vice President of Business Operations | — | — | — | — | — |
Cassie Saitow | Senior Director of IR & Corporate Communications | — | — | — | — | — |
Michelle Patterson | Senior Vice President of Corporate Planning & Portfolio Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Peer companies in the same sector
No competitor data available.
Who manages AVLN?
Avalyn Pharma Inc. Common Stock (AVLN) lists 10 active executives. The top listed executive is Craig Conoscenti, Senior Vice President of Clinical Development.
Explore More
Continue the stock analysis
Jump to another research area for this company.